Mannatech, Incorporated (MTEX) AI Stock Analysis
MTEX AI stock analysis summary
AI ResearchMannatech, Incorporated (MTEX) is a global health and wellness company specializing in nutritional supplements, skincare, and weight-management products. Over the trailing twelve months, the company recorded $107.4M in revenue with a net profit margin of -6.9% and an EPS of -$3.91. As of June 30, 2026, the company holds a market capitalization of $13.7M alongside negative shareholders' equity of -$5.0M.
- Market cap
- $13.7M
- Revenue (TTM)
- $107.4M
- P/E
- — fwd 9.6x
- 1Y return
- -19.7% S&P 500 16.8%
- Avg. target
- $20.00 180.5% vs last close
Bull case
- Mannatech demonstrated positive quarterly momentum in the quarter ended June 30, 2026, with quarterly revenue growth of 3.8% and quarterly earnings growth of 95.7%.
- The stock trades at an EV/EBITDA multiple of 2.5x, well below the median of 11.7x for its US-listed Consumer Defensive peers.
- Insider alignment is substantial, with corporate insiders holding 59.3% of the company's shares.
Bear case
- Mannatech reported negative shareholders' equity of -$5.0M as of June 30, 2026, alongside net debt of $2.5M.
- Long-term sales have contracted, marked by a 5-year revenue CAGR of -6.5% and a net loss of -$15.2M in FY2025.
- Cash flow generation was negative in FY2025, with free cash flow of -$4.3M and operating cash flow of -$3.0M.
What Mannatech does
Headquartered in Flower Mound, Texas, Mannatech, Incorporated operates in the health and wellness sector. Founded in 1993, the company develops, markets, and sells nutritional supplements, topical and skincare solutions, anti-aging products, and weight-management items. Mannatech reaches customers globally through a multi-faceted distribution strategy that combines direct sales, e-commerce platforms, and network marketing channels. The company focuses on offering scientifically-backed health solutions across various demographic and geographic regions.
Growth and profitability
Mannatech experienced a 5-year revenue CAGR of -6.5% between FY2020 and FY2025. Annual revenue decreased from $159.8M in FY2021 to $137.2M in FY2022, $132.0M in FY2023, and $117.9M in FY2024. In FY2025, revenue fell 8.3% to $108.0M, while gross margin declined to 74.9% and net income dropped to -$15.2M from $2.5M in FY2024. Operating margin was -0.4% in FY2025, down from 1.2% in FY2024. In the latest quarter ended June 30, 2026, quarterly revenue grew 3.8% year-over-year and quarterly earnings grew 95.7%, bringing trailing twelve month revenue to $107.4M with an operating margin of 3.8%.
Balance sheet and cash flow
As of June 30, 2026, Mannatech held $6.0M in cash and short-term investments against total debt of $8.5M, resulting in net debt of $2.5M. Total assets stood at $27.5M, and the current ratio was 1.15. The company reported negative shareholders' equity of -$5.0M. During FY2025, operating cash flow was -$3.0M and free cash flow was -$4.3M, while capital expenditures totaled $1.4M. Over the past five years, the company reduced its share count by 6.7%.
Valuation and performance
Mannatech closed at $7.13 on October 16, 2026, representing a market capitalization of $13.7M and an enterprise value of $16.4M. Its forward P/E of 9.6x sits below the 14.3x median of its US-listed Consumer Defensive peers. The stock trades at an EV/EBITDA of 2.5x and a price-to-sales ratio of 0.1x, both lower than peer medians of 11.7x and 0.7x, respectively. Over the trailing year, the stock returned -19.7% compared to 16.8% for the S&P 500. Over five years, the stock dropped 77.6% while the S&P 500 gained 83.0%.
What analysts expect
Wall Street coverage for Mannatech shows a mean price target of $20.00. This target implies an upside of 180.5% compared to the stock's closing price of $7.13 on October 16, 2026. The company is scheduled to report its next financial results on November 11, 2026.
Key risks and what to watch
- Negative shareholders' equity of -$5.0M and cash reserves of $6.0M against $8.5M in debt present balance sheet challenges.
- Sustained annual revenue contraction from $159.8M in FY2021 to $108.0M in FY2025 poses risks to business stability.
- Cash burn remains a factor to watch after the company posted -$3.0M in operating cash flow for FY2025.
- A 5-year price return of -77.6% indicates ongoing market underperformance relative to broader indices.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this MTEX AI stock analysis
This page is an AI-written research summary of Mannatech, Incorporated (MTEX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: MTEX income statement, MTEX balance sheet, MTEX key metrics, MTEX chart. See the MTEX stock overview for the latest quote and news.
MTEX AI stock analysis FAQ
What was Mannatech's revenue in FY2025?
Mannatech generated revenue of $108.0M in FY2025, down 8.3% from $117.9M in FY2024.
What is Mannatech's balance sheet position?
As of June 30, 2026, Mannatech had $6.0M in cash and short-term investments, $8.5M in total debt, and negative shareholders' equity of -$5.0M.
Who owns Mannatech stock?
Insiders hold 59.3% of Mannatech's shares, institutions hold 15.1%, and short interest accounts for 1.2% of the float.
What is the analyst price target for MTEX?
The mean analyst price target is $20.00, which sits 180.5% above the closing price of $7.13 on October 16, 2026.